Bank of New York Mellon Corp - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 45 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2019$17,000
-59.5%
25,0560.0%0.00%
Q2 2019$42,000
-33.3%
25,0560.0%0.00%
Q1 2019$63,000
-3.1%
25,056
-2.8%
0.00%
Q4 2018$65,000
-50.0%
25,7830.0%0.00%
Q3 2018$130,000
+54.8%
25,783
-0.0%
0.00%
Q2 2018$84,000
-9.7%
25,784
-0.1%
0.00%
Q1 2018$93,000
+75.5%
25,809
-17.1%
0.00%
Q3 2017$53,000
-31.2%
31,144
+7.6%
0.00%
Q2 2017$77,00028,9440.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q3 2019
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 4,758,426$3,340,0002.33%
PERKINS CAPITAL MANAGEMENT INC 2,527,000$1,774,0001.59%
Cowen Prime Services LLC 2,137,900$1,501,0000.69%
HighMark Wealth Management LLC 192,000$134,0000.14%
Nantahala Capital Management 5,000,000$3,510,0000.11%
Kalos Management, Inc. 66,900$48,0000.02%
FNY Investment Advisers, LLC 20,500$14,0000.00%
Virtu Financial LLC 31,991$22,0000.00%
Engineers Gate Manager LP 25,440$18,0000.00%
BlackRock Inc. 405,725$285,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders